虎嗅APP·2026-03-02 09:43Core Viewpoint - The article discusses the challenges and potential catalysts for Hengrui Medicine, highlighting the need for stable revenue contributions from BD transactions and the growth of innovative drug sales to restore market confidence [5][52]. Group 1: Current Market Situation - Hengrui Medicine has not seen significant market performance recently, contrasting with peers like Rongchang Biopharmaceutical and Geely Pharmaceutical, which have experienced double-digit stock price increases [4]. - Despite a warming capital market, Hengrui has faced a rare "eleven consecutive declines" in stock price, leading to negative annual fluctuations [4][5]. Group 2: BD Transactions and Performance - BD transactions have become a crucial driver for Hengrui's performance since 2024, but concerns about the sustainability of this model have emerged due to delayed revenue recognition [9][17]. - In 2023, Hengrui received €160 million (approximately RMB 1.2 billion) from BD transactions, and in 2024, it expects to confirm $100 million (approximately RMB 700 million) from Kailera Therapeutics [9][10]. - The company completed five BD transactions before September 2025, securing $783 million and €15 million in upfront payments, along with potential milestone payments totaling $15.8 billion, indicating a significant increase in transaction frequency and scale [13]. Group 3: Innovation and Product Pipeline - Hengrui's innovative drug sales and licensing revenue reached RMB 95.61 billion in the first half of 2025, accounting for about 60% of total revenue, indicating a shift towards "innovation-driven" growth [24]. - The company has received approvals for 17 innovative drugs from 2021 to 2024, creating a diversified product matrix that reduces reliance on single blockbuster products [23]. - Hengrui's innovative drugs, such as Haiqubopai, have shown strong market potential, with sales expected to exceed RMB 1 billion in 2024 [23]. Group 4: Challenges Ahead - Hengrui faces challenges, including a reliance on a "fast-follow" research model, which raises concerns about competition from similar products in the market [30]. - The company lacks a globally recognized blockbuster product, with its most successful products primarily concentrated in the domestic market [32][33]. - Hengrui's internationalization efforts are still in the early stages, with no innovative products approved for sale in overseas markets yet [34]. Group 5: Future Catalysts - Key signals to watch for include the maturation of the BD business model, sustained growth in innovative drug revenue (targeting a compound annual growth rate of over 25%), and breakthroughs in the research pipeline [39][41][42]. - The upcoming FDA review of Hengrui's "dual-Ai" therapy for liver cancer is a critical milestone that could significantly impact the company's international strategy and market perception [49][50].